<DOC>
	<DOCNO>NCT03059979</DOCNO>
	<brief_summary>This 12 week double-blind randomize placebo control trial 30 patient early SSc , fulfil Very Early Diagnosis Of Systemic Sclerosis ( VEDOSS ) criterion ( 9 ) randomize 2:1 fashion receive intravenous methylprednisolone placebo . Three-day treatment course give week 0 , week 4 week 8 . The final assessment week 12 , patient follow one year baseline</brief_summary>
	<brief_title>The Effect High Dose Methylprednisolone Nailfold Early Systemic Sclerosis ( SSc )</brief_title>
	<detailed_description>Systemic sclerosis disease high burden cause morbidity increase mortality . To date cure SSc available . In trial , patient treat early disease could change long term outcome SSc patient . In daily practice , patient early disease course treat although might risk early escalation internal organ involvement , reduce prognosis . A trial investigate efficacy relative save , inexpensive easy accessible treatment provide u opportunity change disease course reduce disease burden portion SSc patient</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Written inform consent Age 18 year Fulfilling VEDOSS criterion ( 9 ) : Raynauds ' Phenomenon Positive disease specific auto antibody ( anticentromere antitopoisomerase antibody ) typical nail fold capillaroscopic finding Puffy finger &lt; 3 year Modified Rodnan skin score = 0 Presence acroosclerosis , acrosteolysis digital ulcer Presence antiRNA polymerase III auto antibody Previous systemic treatment SSc , namely : methotrexate , prednisone ( &gt; 14 day previous 6 month ) , mofetil mycophenolate cyclophosphamide . Clinically significant internal organ involvement : diffusion capacity lung carbon monoxide ( DLCO ) &lt; 80 % predict , vital capacity ( VC ) &lt; 70 % predict renal dysfunction glomerular filtration rate ( GFR ) &lt; 60 ml/min diastolic dysfunction &gt; grade 1 echocardiography pulmonary hypertension weight loss &gt; 10 % last 6 month unknown cause Contraindications methylprednisolone , : pregnancy , lactation psychotic depressive disorder ulcus duodeni ventriculus untreated hypertension ( &gt; 16090 mmHg ) acute infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>